Up to date knowledge on different treatment strategies for phenylketonuria

Molecular Genetics and Metabolism

Volumn 104, Issue SUPPL., 2011, Pages

  Bélanger Quintana, Amaya ^a   Burlina, Alberto ^b   Harding, Cary O ^c   Muntau, Ania C ^d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Gene therapy; Phenylalanine ammonia lyase; Phenylketonuria; Sapropterin; Tetrahydrobiopterin

Indexed keywords

PHENYLALANINE; PHENYLALANINE AMMONIA LYASE; RECOMBINANT ENZYME; SAPROPTERIN; TETRAHYDROBIOPTERIN;

ABSENCE OF SIDE EFFECTS; ANABAENA VARIABILIS; DIARRHEA; DIET THERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENE THERAPY; GENOTYPE; HEADACHE; HUMAN; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; NUTRITIONAL DEFICIENCY; PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN INTAKE; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

BIOPTERIN; GENE THERAPY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PHENYLALANINE AMMONIA-LYASE; PHENYLKETONURIAS;

EID: 82755189346     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.08.009     Document Type: Review

References (93)

1. Scriver C.R., Kaufman S. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. The Metabolic and Molecular Bases of Inherited Disease 2001, McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, D. Valle, B. Vogelstein, W.S. Sly (Eds.).
2. Woolf L.I. Excretion of conjugated phenylacetic acid in phenylketonuria. Biochem. J. 1951, 49:ix-x.
3. Bickel H., Gerrard J., Hickmans E.M. Influence of phenylalanine intake on phenylketonuria. Lancet 1953, 265:812-813.
4. National institutes of health consensus development conference statement: phenylketonuria: screening and management. Pediatrics 2000, 108:972-982.
5. Enns G.M., Koch R., Brumm V., Blakely E., Suter R., Jurecki e. Suboptimal outcome in patients with PKU treated early with diet alone: revisiting the evidence. Mol. Genet. Metab. 2010, 101:99-109.
6. Levy H.L., Waisbren S.E., Güttler F., Hanley W.B., Matalon R., Rouse B., Trefz F.K., de la Cruz F., Azen C.G., Koch R. Pregnancy experiences in the woman with mild hyperphenylalaninemia. Pediatrics 2003, 112:1548-1552.
7. Feillet F., van Spronsen F.J., MacDonald A., Trefz F.K., Demirkol M., Giovannini M., Bélanger-Quintana A., Blau N. Challenges and pitfalls in the management of phenylketonuria. Pediatrics Aug 2010, 126(2):333-341. Epub 2010 Jul 12.
8. Acosta P.B., Yannicelli S., Singh R., Mofidi S., Steiner R., DeVincentis E., Jurecki E., Bernstein L., Gleason S., Chetty M., Rouse B. Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J. Am. Diet. Assoc. 2003, 103:1167-1173.
9. Arnold G.L., Vladutiu C.J., Kirby R.S., Blakely E.m, Deluca J.M. Protein insufficiency and linear growth restriction in phenylketonuria. J. Pediatr. 2002, 141:243-246.
10. Dobbelaere D., Michaud L., Debrabander A., Vanderbecken S., Gottrand F., Turck D., Farriaux J.P. Evaluation of nutritional status and pathophysiology of growth retardation in patients with phenylketonuria. J. Inherit. Metab. Dis. 2003, 26:1-11.
11. Barat P., Barthe N., Redonnet-Vernhet I., Parrot F. The impact of the control of serum phenylalanine levels on osteopenia in patients with phenylketonuria. Eur. J. Pediatr. 2002, 161:687-688.
12. Simon E., Schwarz M., Roos J., Dragano N., Geraedts M., Siegrist J., Kamp G., Wendel U. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual. Life Outcomes 2008, 26:6-25.
13. Ahring K., Bélanger-Quintana A., Dokoupil K., Gokmen-Ozel H., Lammardo A.M., MacDonald A., Motzfeldt K., Nowacka M., Robert M., van Rijn M. Blood phenylalanine control in phenylketonuria: a survey of 10 European centres. Eur. J. Clin. Nutr. 2011, 65:275-278.
14. MacDonald A., Gokmen-Ozel H., van Rijn M., Burgard P. The reality of dietary compliance in the management of phenylketonuria. J. Inherit. Metab. Dis. 2010, 33:665-670.
15. Waisbren S.E., Noel K., Fahrbach K., Cella C., Frame D., Dorenbaum A., Levy H. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol. Genet. Metab. 2007, 92:63-70.
16. Gassió R., Artuch R., Vilaseca M.A., Fusté E., Boix C., Sans A., Campistol J. Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population. Dev. Med. Child Neurol. 2005, 47:443-448.
17. Gentile J.K., Ten Hoedt A.E., Bosch A.M. Psychosocial aspects of PKU: hidden disabilities-a review. Mol. Genet. Metab. 2010, 99:S64-S67.
18. Christ S.E., Huijbregts S.C., de Sonneville L.M., White D.A. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol. Genet. Metab. 2010, 99:S22-S32.
19. Sharman R., Sullivan K., Young R., McGill J. Biochemical markers associated with executive function in adolescents with early and continuously treated phenylketonuria. Clin. Genet. 2009, 75:169-174.
20. Leuzzi V., Pansini M., Sechi E., Chiarotti F., Carducci C., Levi G., Antonozzi I. Executive function impairment in early-treated PKU subjects with normal mental development. J. Inherit. Metab. Dis. 2004, 27:115-125.
21. Brumm V.L., Bilder D., Waisbren S.E. Psychiatric symptoms and disorders in phenylketonuria. Mol. Genet. Metab. 2010, 99:S59-S63.
22. Matalon R., Michals-Matalon K., Bhatia G., Burlina A.B., Burlina A.P., Braga C., Fiori L., Giovannini M., Grechanina E., Novikov P., Grady J., Tyring S.K., Guttler F. Double blind placebo control trial of large neutral aminoacids in treatment of PKU: effect on blood phenylalanine. J. Inherit. Metab. Dis. 2007, 30:153-158.
23. Ney D.M., Gleason S.T., van Calcar S.C., MacLeod E.L., Nelson K.L., Etzel M.R., Rice G.M., Wolff J.A. Nutritional management of PKU with glycomacropeptide from cheese whey. J. Inherit. Metab. Dis. 2009, 32:32-38.
24. Harding C.O., Gibson K.M. Therapeutic liver repopulation for phenylketonuria. J. Inherit. Metab. Dis. 2010, 33:681-687.
25. Hyghland K. Tetrahydrobiopterin deficiencies with hyperphenylalaninemia. PKU and BH4. Advances in Phenylketonuria and Tetrahydrobiopterin 2006, SPS Publications. N. Blau (Ed.).
26. Niederwieser A., Curtius H.C., Wang M., Leupold D. Atypical phenylketonuria with defective biopterin metabolism. Monotherapy with tetrahydrobiopterin or sepiapterin, screening and study of biosynthesis in man. Eur. J. Pediatr. 1982, 138:110-112.
27. Kure S., Hou D.C., Ohura T., Iwamoto H., Suzuki S., Sugiyama N., Sakamoto O., Fujii K., Matsubara Y., Narisawa K. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J. Pediatr. 1999, 135:375-378.
28. Bernegger C., Blau N. High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002. Mol. Genet. Metab. 2002, 77:304-313.
29. Muntau A.C., Röschinger W., Habich M., Demmelmair H., Hoffmann B., Sommerhoff C.P., Roscher A.A. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med. 2002, 347:2122-2132.
30. Lindner M., Steinfeld R., Burgard P., Schulze A., Mayatepek E., Zschocke J. Tetrahydrobiopterin sensitivity in German patients with mild phenylalanine hydroxylase deficiency. Hum. Mutat. 2003, 21:400.
31. Desviat L.R., Pérez B., Bèlanger-Quintana A., Castro M., Aguado C., Sánchez A., García M.J., Martínez-Pardo M., Ugarte M. Tetrahydrobiopterin responsiveness: results of the BH4 loading test in 31 Spanish PKU patients and correlation with their genotype. Mol. Genet. Metab. 2004, 83:157-162.
32. Matalon R., Michals-Matalon K., Koch R., Grady J., Tyring S., Stevens R.C. Response of patients with phenylketonuria in the US to tetrahydrobiopterin. Mol. Genet. Metab. 2005, 86:S17-S21.
33. Mitchell J.J., Wilcken B., Alexander I., Ellaway C., O'Grady H., Wiley V., Earl J., Christodoulou J. Tetrahydrobiopterin-responsive phenylketonuria: the New South Wales experience. Mol. Genet. Metab. 2005, 86:S81-S85.
34. Zurflüh M.R., Zschocke J., Lindner M., Feillet F., Chery C., Burlina A., Stevens R.C., Thöny B., Blau N. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum. Mutat. 2008, 29:167-175.
35. Dobrowolski S.F., Borski K., Ellingson C.C., Koch R., Levy H.L., Naylor E.W. A limited spectrum of phenylalanine hydroxylase mutations is observed in phenylketonuria patients in western Poland and implications for treatment with 6R tetrahydrobiopterin. J. Hum. Genet. 2009, 54:335-359.
36. Karacić I., Meili D., Sarnavka V., Heintz C., Thöny B., Ramadza D.P., Fumić K., Mardesić D., Barić I., Blau N. Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency. Mol. Genet. Metab. 2009, 97:165-171.
37. Blau N., Bélanger-Quintana A., Demirkol M., Feillet F., Giovannini M., MacDonald A., Trefz F.K., van Spronsen F.J. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol. Genet. Metab. 2009, 96:158-163.
38. Levy H., Burton B., Cederbaum S., Scriver C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Mol. Genet. Metab. 2007, 92:287-291.
39. Fiege B., Bonafé L., Ballhausen D., Baumgartner M., Thöny B., Meili D., Fiori L., Giovannini M., Blau N. Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study. Mol. Genet. Metab. 2005, 86:S91-S95.
40. Okano Y., Takatori K., Kudo S., Sakaguchi T., Asada M., Kajiwara M., Yamano T. Effects of tetrahydrobiopterin and phenylalanine on in vivo human phenylalanine hydroxylase by phenylalanine breath test. Mol. Genet. Metab. 2007, 92:308-314.
41. Pey A.L., Stricher F., Serrano L., Martinez A. Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am. J. Hum. Genet. 2007, 81:1006-1024.
42. Gersting S.W., Kemter K.F., Staudigl M., Messing D.D., Danecka M.K., Lagler F.B., Sommerhoff C.P., Roscher A.A., Muntau A.C. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am. J. Hum. Genet. 2008, 83:5-17.
43. Erlandsen H., Pey A.L., Gámez A., Pérez B., Desviat L.R., Aguado C., Koch R., Surendran S., Tyring S., Matalon R., Scriver C.R., Ugarte M., Martínez A., Stevens R.C. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16903-16908.
44. Pey A.L., Pérez B., Desviat L.R., Martínez M.A., Aguado C., Erlandsen H., Gámez A., Stevens R.C., Thórólfsson M., Ugarte M., Martínez A. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum. Mutat. 2004, 24:388-399.
45. Pérez B., Desviat L.R., Gómez-Puertas P., Martínez A., Stevens R.C., Ugarte M. Kinetic and stability analysis of PKU mutations identified in BH4-responsive patients. Mol. Genet. Metab. 2005, 86:S11-S16.
46. Gersting S.W., Lagler F.B., Eichinger A., Kemter K.F., Danecka M.K., Messing D.D., Staudigl M., Domdey K.A., Zsifkovits C., Fingerhut R., Glossmann H., Roscher A.A., Muntau A.C. Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. Hum. Mol. Genet. 2010, 19:2039-2049.
47. Hennermann J.B., Bührer C., Blau N., Vetter B., Mönch E. Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol. Genet. Metab. 2005, 86:S86-S90.
48. Trefz F.K., Scheible D., Götz H., Frauendienst-Egger G. Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria. J. Inherit. Metab. Dis. 2009, 32:22-26.
49. Staudigl M., Gersting S.W., Danecka M.K., Messing D.D., Woidy M., Pinkas D., Kemter K.F., Blau N., Muntau A.C. The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response. Hum. Mol. Genet. 2011, [Epub ahead of print].
50. Feillet F., Chery C., Namour F., Kimmoun A., Favre E., Lorentz E., Battaglia-Hsu S.F., Guéant J.L. Evaluation of neonatal BH4 loading test in neonates screened for hyperphenylalaninemia. Early Hum. Dev. 2008, 84:561-567.
51. Bik-Multanowski M., Pietrzyk J.J., Didycz B., Szymczakiewicz-Multanowska A. Development of a model for assessment of phenylalanine hydroxylase activity in newborns with phenylketonuria receiving tetrahydrobiopterin: a potential for practical implementation. Mol. Genet. Metab. 2008, 94:389-390.
52. Burton B.K., Adams D.J., Grange D.K., Malone J.I., Jurecki E., Bausell H., Marra K.D., Sprietsma L., Swan K.T. Tetrahydrobiopterin therapy for phenylketonuria in infants and young children. J. Pediatr. 2011, 158:410-415.
53. Lee P., Treacy E.P., Crombez E., Wasserstein M., Waber L., Wolff J., Wendel U., Dorenbaum A., Bebchuk J., Christ-Schmidt H., Seashore M., Giovannini M., Burton B.K., Morris A.A. Safety and efficacy of 22weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am. J. Med. Genet. A 2008, 15:2851-2859. Sapropterin Research Group.
54. Feillet F., Clarke L., Meli C., Lipson M., Morris A.A., Harmatz P., Mould D.R., Green B., Dorenbaum A., Giovannini M., Foehr E. Pharmacokinetics of sapropterin in patients with phenylketonuria. Clin. Pharmacokinet. 2008, 47:817-825. Sapropterin Research Group.
55. Cerone R., Schiaffino M.C., Fantasia A.R., Perfumo M., Birk Moller L., Blau N. Long-term follow-up of a patient with mild tetrahydrobiopterin-responsive phenylketonuria. Mol. Genet. Metab. 2004, 81:137-139.
56. Lambruschini N., Pérez-Dueñas B., Vilaseca M.A., Mas A., Artuch R., Gassió R., Gómez L., Gutiérrez A., Campistol J. Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol. Genet. Metab. 2005, 86:S54-S60.
57. Bélanger-Quintana A., García M.J., Castro M., Desviat L.R., Pérez B., Mejía B., Ugarte M., Martínez-Pardo M. Spanish BH4-responsive phenylalanine hydroxylase-deficient patients: evolution of seven patients on long-term treatment with tetrahydrobiopterin. Mol. Genet. Metab. 2005, 86:S61-S66.
58. Trefz F.K., Scheible D., Frauendienst-Egger G., Korall H., Blau N. Long-term treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterin. Mol. Genet. Metab. 2005, 86:S75-S80.
59. Bóveda M.D., Couce M.L., Castiñeiras D.E., Cocho J.A., Pérez B., Ugarte M., Fraga J.M. The tetrahydrobiopterin loading test in 36 patients with hyperphenylalaninaemia: evaluation of response and subsequent treatment. J. Inherit. Metab. Dis. 2007, 30:812.
60. Trefz F.K., Scheible D., Frauendienst-Egger G. Long-term follow-up of patients with phenylketonuria receiving tetrahydrobiopterin treatment. J. Inherit. Metab. Dis. 2010, 9. [Epub ahead of print].
61. Lagler F.B., Gersting S.W., Zsifkovits C., Steinbacher A., Eichinger A., Danecka M.K., Staudigl M., Fingerhut R., Glossmann H., Muntau A.C. New insights into tetrahydrobiopterin pharmacodynamics from Pah enu1/2, a mouse model for compound heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Biochem. Pharmacol. 2010, 80:1563-1571.
62. Musson D.G., Kramer W.G., Foehr E.D., Bieberdorf F.A., Hornfeldt C.S., Kim S.S., Dorenbaum A. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults. Clin. Ther. 2010, 32:338-346.
63. Macdonald A., Ahring K., Dokoupil K., Gokmen-Ozel H., Lammardo A.M., Motzfeldt K., Robert M., Rocha J.C., van Rijn M., Bélanger-Quintana A. Adjusting diet with sapropterin in phenylketonuria: what factors should be considered?. Br. J. Nutr. 2011, 5:1-8.
64. Singh R.H., Jurecki E., Rohr F. Recommendations for personalized diet adjustments based on patients response to tetrahydrobiopterin (BH4) in phenylketonuria. Top. Clin. Nutr. 2008, 23:149-157.
65. Shintaku H., Kure S., Ohura T., Okano Y., Ohwada M., Sugiyama N., Sakura N., Yoshida I., Yoshino M., Matsubara Y., Suzuki K., Aoki K., Kitagawa T. Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene. Pediatr. Res. 2004, 55:425-430.
66. Shintaku H., Ohwada M., Aoki K., Kitagawa T., Yamano T. Diagnosis of tetrahydrobiopterin (BH4) responsive mild phenylketonuria in Japan over the past 10years. Ann. Acad. Med. Singapore 2008, 37:77-82.
67. Burton B.K., Bausell H., Katz R., Laduca H., Sullivan C. Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU). Mol. Genet. Metab. 2010, 101:110-114.
68. Singh R.H., Quirk M.E., Douglas T.D., Brauchla M.C. BH(4) therapy impacts the nutrition status and intake in children with phenylketonuria: 2-year follow-up. J. Inherit. Metab. Dis. 2010, 33:689-695.
69. Vilaseca M.A., Lambruschini N., Gómez-López L., Gutiérrez A., Moreno J., Tondo M., Artuch R., Campistol J. Long-chain polyunsaturated fatty acid status in phenylketonuric patients treated with tetrahydrobiopterin. Clin. Biochem. 2010, 43:411-415.
70. Gassió R., Vilaseca M.A., Lambruschini N., Boix C., Fusté M.E., Campistol J. Cognitive functions in patients with phenylketonuria in long-term treatment with tetrahydrobiopterin. Mol. Genet. Metab. 2010, 99:S75-S78.
71. Somaraju U.R., Merrin M. Sapropterin dihydrochloride for phenylketonuria. Cochrane Database Syst. Rev. 2010, 16:CD008005.
72. Opladen T., Zurflüh M., Kern I., Kierat L., Thöny B., Blau N. Severe mucitis after sublingual administration of tetrahydrobiopterin in a patient with tetrahydrobiopterin-responsive phenylketonuria. Eur. J. Pediatr. 2005, 164:395-396.
73. Burton B.K., Grange D.K., Milanowski A., Vockley G., Feillet F., Crombez E.A., Abadie V., Harding C.O., Cederbaum S., Dobbelaere D., Smith A., Dorenbaum A. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J. Inherit. Metab. Dis. 2007, 30:700-707.
74. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., Whitley C.B., Feillet F., Feigenbaum A.S., Bebchuk J.D., Christ-Schmidt H., Dorenbaum A. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007, 370:504-510. Sapropterin Research Group.
75. Trefz F.K., Burton B.K., Longo N., Casanova M.M., Gruskin D.J., Dorenbaum A., Kakkis E.D., Crombez E.A., Grange D.K., Harmatz P., Lipson M.H., Milanowski A., Randolph L.M., Vockley J., Whitley C.B., Wolff J.A., Bebchuk J., Christ-Schmidt H., Hennermann J.B. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J. Pediatr. 2009, 154:700-707. Sapropterin Study Group.
76. Koch R. Maternal phenylketonuria and tetrahydrobiopterin. Pediatrics 2008, 122:1367-1368.
77. Trefz F.K., Belanger-Quintana A. Sapropterin dihydrochloride: a new drug and a new concept in the management of phenylketonuria. Drugs Today 2010, 46:589-600.
78. Kim W., Erlandsen H., Surendran S., Stevens R.C., Gamez A., Michols-Matalon K., Tyring S.K., Matalon R. Trends in enzyme therapy for phenylketonuria. Mol. Ther. 2004, 10:220-224.
79. Hoskins J.A., Holliday S.B., Greenway A.M. The metabolism of cinnamic acid by healthy and phenylketonuric adults: a kinetic study. Biomed. Mass Spectrom. 1984, 11:296-300.
80. Hoskins J.A., Jack G., Wade H.E., Peiris R.J., Wright E.C., Starr D.J., Stern J. Enzymatic control of phenylalanine intake in phenylketonuria. Lancet 1980, 1:392-394.
81. Safos S., Chang T.M. Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report. Artif. Cells Blood Substit. Immobil. Biotechnol. 1995, 23:681-692.
82. Ambrus C.M., Ambrus J.L., Horvath C., Pedersen H., Sharma S., Kant C., Mirand E., Guthrie R., Paul T. Phenylalanine depletion for the management of phenylketonuria: use of enzyme reactors with immobilized enzymes. Science 1978, 201:837-839.
83. Sarkissian C.N., Gamez A., Wang L., Charbonneau M., Fitzpatrick P., Lemontt J.F., Zhao B., Vellard M., Bell S.M., Henschell C., Lambert A., Tsuruda L., Stevens R.C., Scriver C.R. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20894-20899.
84. Sarkissian C.N., Shao Z., Blain F., Peevers R., Su H., Heft R., Chang T.M., Scriver C.R. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2339-2344.
85. Gamez A., Wang L., Sarkissian C.N., Wendt D., Fitzpatrick P., Lemontt J.F., Scriver C.R., Stevens R.C. Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria. Mol. Genet. Metab. 2007, 91:325-334.
86. Kang T.S., Wang L., Sarkissian C.N., Gámez A., Scriver C.R., Stevens R.C. Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria. Mol. Genet. Metab. 2010, 99:4-9.
87. Woo S.L., Lidsky A.S., Güttler F., Chandra T., Robson K.J. Cloned human phenylalanine hydroxylase gene allows prenatal diagnosis and carrier detection of classical phenylketonuria. Nature 1983, 306:151-155.
88. Ledley F.D., Grenett H.E., DiLella A.G., Kwok S.C., Woo S.L. Gene transfer and expression of human phenylalanine hydroxylase. Science 1985, 228:77-79.
89. Harding C.O., Gillingham M.B., Hamman K., Clark H., Goebel-Daghighi E., Bird A., Koeberl D.D. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria. Gene Ther. 2006, 13:457-462.
90. Ding Z., Georgiev P., Thöny B. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. Gene Ther. 2006, 13:587-593.
91. Ding Z., Harding C.O., Rebuffat A., Elzaouk L., Wolff J.A., Thöny B. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol. Ther. 2008, 16:673-681.
92. Rebuffat A., Harding C.O., Ding Z., Thöny B. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Hum. Gene Ther. 2010, 21:463-477.
93. Alexander I.E., Cunningham S.C., Logan G.J., Christodoulou J. Potential of AAV vectors in the treatment of metabolic disease. Gene Ther. 2008, 15:831-839.